Register for our free email digests:
Latest From Hangzhou Minsheng Pharmaceutical Group Co. Ltd.
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.
After the recent acquisition of a local OTC firm, PharmAsia News takes a closer look at Bayer’s aims of becoming the leader in the OTC sector in China.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
With China the main engine of growth for multinational drug firms in emerging markets, PharmAsia News takes a closer look at companies’ China earnings, finding some strong Q3 sales figures, but slowdowns for others.
- Gene Therapy, Cell Therapy
- Medical Devices
- Therapeutic Areas
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- Reapplix APS
- Senior Management
Niels E Holm, PhD, CEO
Rasmus Lundquist, CSO
- Contact Info
Phone: 88 16 80 66
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.